- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 23 Mar 22 424B3 Prospectus supplement
- 23 Mar 22 EFFECT Notice of effectiveness
- 18 Mar 22 POS AM Prospectus update (post-effective amendment)
- 15 Nov 21 424B3 Prospectus supplement
- 21 Sep 21 424B3 Prospectus supplement
- 16 Aug 21 424B3 Prospectus supplement
- 28 May 21 POS EX Additional exhibits for listing
- 28 May 21 424B4 Prospectus supplement with pricing info
- 27 May 21 EFFECT Notice of effectiveness
-
25 May 21 S-1/A IPO registration (amended)
- 19 May 21 S-1/A IPO registration (amended)
- 10 May 21 S-1/A IPO registration (amended)
- 19 Apr 21 S-1 IPO registration
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the inclusion in this Amendment No. 3 to the Registration Statement on Form S-1 (File No. 333-255323) of our report dated March 22, 2021, except for the effect of restatement disclosed in Note 2 and Note 9, as to which the date is May 7, 2021 with respect to our audit of the consolidated balance sheets of Reviva Pharmaceuticals Holdings, Inc. as of December 31, 2020 and 2019, the related consolidated statements of operations, stockholders' equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2020, and the related notes to the consolidated financial statements. We also consent to the reference to our firm under the heading "Experts" in this Registration Statement.
/s/ Armanino LLP San Ramon, California |
May 25, 2021